Difference between revisions of "Stem cell mobilization regimens"
m (→References) |
|||
Line 29: | Line 29: | ||
|- | |- | ||
|} | |} | ||
− | ==== | + | ====Chemotherapy==== |
*[[Cyclophosphamide (Cytoxan)]] 1500 mg/m<sup>2</sup> IV once on day 1 | *[[Cyclophosphamide (Cytoxan)]] 1500 mg/m<sup>2</sup> IV once on day 1 | ||
+ | ====Growth factor therapy==== | ||
*[[Lenograstim (Granocyte)]] 263 mcg SC once per day starting on day 4 | *[[Lenograstim (Granocyte)]] 263 mcg SC once per day starting on day 4 | ||
Line 44: | Line 45: | ||
|- | |- | ||
|} | |} | ||
− | ==== | + | ====Chemotherapy==== |
*[[Cyclophosphamide (Cytoxan)]] 3000 mg/m<sup>2</sup> IV once | *[[Cyclophosphamide (Cytoxan)]] 3000 mg/m<sup>2</sup> IV once | ||
+ | ====Growth factor therapy==== | ||
*[[Filgrastim (Neupogen)]] 10 mcg/kg SC once per day and continued until at least 4 × 10<sup>6</sup> CD34+ cells/kg are collected | *[[Filgrastim (Neupogen)]] 10 mcg/kg SC once per day and continued until at least 4 × 10<sup>6</sup> CD34+ cells/kg are collected | ||
Line 68: | Line 70: | ||
|- | |- | ||
|} | |} | ||
− | ==== | + | ====Chemotherapy==== |
*[[Cytarabine (Cytosar)]] 3000 mg/m<sup>2</sup> IV once per day on days 1 & 2 | *[[Cytarabine (Cytosar)]] 3000 mg/m<sup>2</sup> IV once per day on days 1 & 2 | ||
+ | ====Growth factor therapy==== | ||
*[[Filgrastim (Neupogen)]] 10 mcg/kg SC once per day starting on day 4 and continued until stem cell collection complete | *[[Filgrastim (Neupogen)]] 10 mcg/kg SC once per day starting on day 4 and continued until stem cell collection complete | ||
Line 90: | Line 93: | ||
|- | |- | ||
|} | |} | ||
− | ==== | + | ====Chemotherapy==== |
*[[Cytarabine (Cytosar)]] 1000 mg/m<sup>2</sup> IV Q12H on days 1 & 2 | *[[Cytarabine (Cytosar)]] 1000 mg/m<sup>2</sup> IV Q12H on days 1 & 2 | ||
*[[Ifosfamide (Ifex)]] 1500 mg/m<sup>2</sup> IV once per day on days 1 to 3 | *[[Ifosfamide (Ifex)]] 1500 mg/m<sup>2</sup> IV once per day on days 1 to 3 | ||
+ | ====Growth factor therapy==== | ||
*[[Filgrastim (Neupogen)]] (dose/frequency not specified) | *[[Filgrastim (Neupogen)]] (dose/frequency not specified) | ||
Line 118: | Line 122: | ||
|} | |} | ||
''Target collection dose not described; mobilization took place after the first course of [[CNS_lymphoma#CYVE|CYVE salvage for CNS lymphoma]].'' | ''Target collection dose not described; mobilization took place after the first course of [[CNS_lymphoma#CYVE|CYVE salvage for CNS lymphoma]].'' | ||
− | ==== | + | ====Chemotherapy==== |
*[[Cytarabine (Cytosar)]] as follows: | *[[Cytarabine (Cytosar)]] as follows: | ||
**2000 mg/m<sup>2</sup> IV over 3 hours once per day on days 2 to 5 | **2000 mg/m<sup>2</sup> IV over 3 hours once per day on days 2 to 5 | ||
**50 mg/m<sup>2</sup> IV over 12 hours once per day on days 1 to 5 | **50 mg/m<sup>2</sup> IV over 12 hours once per day on days 1 to 5 | ||
*[[Etoposide (Vepesid)]] 200 mg/m<sup>2</sup> IV over 2 hours once per day on days 2 to 5 | *[[Etoposide (Vepesid)]] 200 mg/m<sup>2</sup> IV over 2 hours once per day on days 2 to 5 | ||
+ | ====Growth factor therapy==== | ||
*[[Filgrastim (Neupogen)]] 5 mcg/kg SC once per day starting 48 hours after end of chemotherapy | *[[Filgrastim (Neupogen)]] 5 mcg/kg SC once per day starting 48 hours after end of chemotherapy | ||
Line 144: | Line 149: | ||
|- | |- | ||
|} | |} | ||
− | ==== | + | ====Chemotherapy==== |
*[[Ifosfamide (Ifex)]] 2000 mg/m<sup>2</sup> IV over 2 hours once per day on days 1 to 4 | *[[Ifosfamide (Ifex)]] 2000 mg/m<sup>2</sup> IV over 2 hours once per day on days 1 to 4 | ||
*[[Gemcitabine (Gemzar)]] 800 mg/m<sup>2</sup> IV once per day on days 1 & 4 | *[[Gemcitabine (Gemzar)]] 800 mg/m<sup>2</sup> IV once per day on days 1 & 4 | ||
Line 158: | Line 163: | ||
===References=== | ===References=== | ||
# Magagnoli M, Spina M, Balzarotti M, Timofeeva I, Isa L, Michieli M, Capizzuto R, Morenghi E, Castagna L, Tirelli U, Santoro A. IGEV regimen and a fixed dose of lenograstim: an effective mobilization regimen in pretreated Hodgkin's lymphoma patients. Bone Marrow Transplant. 2007 Dec;40(11):1019-25. Epub 2007 Oct 1. [http://www.nature.com/bmt/journal/v40/n11/full/1705862a.html link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17906705 PubMed] | # Magagnoli M, Spina M, Balzarotti M, Timofeeva I, Isa L, Michieli M, Capizzuto R, Morenghi E, Castagna L, Tirelli U, Santoro A. IGEV regimen and a fixed dose of lenograstim: an effective mobilization regimen in pretreated Hodgkin's lymphoma patients. Bone Marrow Transplant. 2007 Dec;40(11):1019-25. Epub 2007 Oct 1. [http://www.nature.com/bmt/journal/v40/n11/full/1705862a.html link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17906705 PubMed] | ||
+ | |||
+ | ==DexaBEAM & G-CSF {{#subobject:542726|Regimen=1}}== | ||
+ | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
+ | |- | ||
+ | |[[#top|back to top]] | ||
+ | |} | ||
+ | DexaBEAM: '''<u>R</u>'''ituximab, '''<u>Dexa</u>'''methasone, '''<u>B</u>'''iCNU (Carmustine), '''<u>E</u>'''toposide, '''<u>A</u>'''ra-C (Cytarabine), '''<u>M</u>'''elphalan | ||
+ | ===Regimen {{#subobject:41ae94|Variant=1}}=== | ||
+ | {| border="1" style="text-align:center;" !align="left" | ||
+ | |'''Study''' | ||
+ | |[[Levels_of_Evidence#Evidence|'''Evidence''']] | ||
+ | |- | ||
+ | |[http://www.bloodjournal.org/content/105/7/2677.long Dreyling et al. 2004] | ||
+ | | style="background-color:#eeee00" |Non-randomized portion of RCT | ||
+ | |- | ||
+ | |} | ||
+ | ====Chemotherapy==== | ||
+ | *[[Dexamethasone (Decadron)]] 8 mg PO TID on days 1 to 10 | ||
+ | *[[Carmustine (BiCNU)]] 60 mg/m<sup>2</sup> IV once on day 2 | ||
+ | *[[Etoposide (Vepesid)]] 75 mg/m<sup>2</sup> IV once per day on days 4 to 7 | ||
+ | *[[Cytarabine (Cytosar)]] 100 mg/m<sup>2</sup> IV BID on days 4 to 7 | ||
+ | *[[Melphalan (Alkeran)]] 20 mg/m<sup>2</sup> IV once on day 3 | ||
+ | |||
+ | ====Growth factor therapy==== | ||
+ | *[[:Category:Granulocyte_growth_factors|G-CSF]] starting on day 11 | ||
+ | |||
+ | ''A minimum of 1 × 10<sup>6</sup> CD34+ cells/kg are collected.'' | ||
+ | |||
+ | ===References=== | ||
+ | # Dreyling M, Lenz G, Hoster E, Van Hoof A, Gisselbrecht C, Schmits R, Metzner B, Truemper L, Reiser M, Steinhauer H, Boiron JM, Boogaerts MA, Aldaoud A, Silingardi V, Kluin-Nelemans HC, Hasford J, Parwaresch R, Unterhalt M, Hiddemann W. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood. 2005 Apr 1;105(7):2677-84. Epub 2004 Dec 9. [http://www.bloodjournal.org/content/105/7/2677.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15591112 PubMed] | ||
[[Category:Stem cell mobilization regimens]] | [[Category:Stem cell mobilization regimens]] | ||
[[Category:Regimen-specific_pages]] | [[Category:Regimen-specific_pages]] |
Revision as of 04:30, 9 November 2017
Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer.
Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are invited to contribute to the site.
Unlike the other chemotherapy regimen pages, this one is not disease-specific. Rather, this is a gathering point for all stem cell mobilization regimens.
11 regimens on this page
13 variants on this page
|
Stem cell mobilization
These are regimens intended to mobilize stem cells, very incomplete right now but will be filled in over time.
Cyclophosphamide & G-CSF
back to top |
Regimen #1
Study | Evidence |
Oakervee et al. 2005 | Phase II |
Chemotherapy
- Cyclophosphamide (Cytoxan) 1500 mg/m2 IV once on day 1
Growth factor therapy
- Lenograstim (Granocyte) 263 mcg SC once per day starting on day 4
Stem cell collection begins on day 10 and continues until at least 2 × 106 CD34+ cells/kg are collected.
Regimen #2
Study | Evidence |
Royer et al. 2016 | Phase II |
Chemotherapy
- Cyclophosphamide (Cytoxan) 3000 mg/m2 IV once
Growth factor therapy
- Filgrastim (Neupogen) 10 mcg/kg SC once per day and continued until at least 4 × 106 CD34+ cells/kg are collected
References
- Oakervee HE, Popat R, Curry N, Smith P, Morris C, Drake M, Agrawal S, Stec J, Schenkein D, Esseltine DL, Cavenagh JD. PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol. 2005 Jun;129(6):755-62. link to original article contains verified protocol PubMed
- Royer B, Minvielle S, Diouf M, Roussel M, Karlin L, Hulin C, Arnulf B, Macro M, Cailleres S, Brion A, Brechignac S, Belhadj K, Chretien ML, Wetterwald M, Chaleteix C, Tiab M, Leleu X, Frenzel L, Garderet L, Choquet S, Fuzibet JG, Dauriac C, Forneker LM, Benboubker L, Facon T, Moreau P, Avet-Loiseau H, Marolleau JP. Bortezomib, Doxorubicin, Cyclophosphamide, Dexamethasone Induction Followed by Stem Cell Transplantation for Primary Plasma Cell Leukemia: A Prospective Phase II Study of the Intergroupe Francophone du Myélome. J Clin Oncol. 2016 Jun 20;34(18):2125-32. Epub 2016 Apr 25. link to original article contains protocol PubMed
Cytarabine & G-CSF
back to top |
Regimen
Study | Evidence |
Abrey et al. 2003 | Phase II |
Chemotherapy
- Cytarabine (Cytosar) 3000 mg/m2 IV once per day on days 1 & 2
Growth factor therapy
- Filgrastim (Neupogen) 10 mcg/kg SC once per day starting on day 4 and continued until stem cell collection complete
References
- Abrey LE, Moskowitz CH, Mason WP, Crump M, Stewart D, Forsyth P, Paleologos N, Correa DD, Anderson ND, Caron D, Zelenetz A, Nimer SD, DeAngelis LM. Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis. J Clin Oncol. 2003 Nov 15;21(22):4151-6. link to original article contains verified protocol PubMed
Cytarabine, Ifosfamide, G-CSF
back to top |
Regimen
Study | Evidence |
Colombat et al. 2006 | Phase II |
Chemotherapy
- Cytarabine (Cytosar) 1000 mg/m2 IV Q12H on days 1 & 2
- Ifosfamide (Ifex) 1500 mg/m2 IV once per day on days 1 to 3
Growth factor therapy
- Filgrastim (Neupogen) (dose/frequency not specified)
References
- Colombat P, Lemevel A, Bertrand P, Delwail V, Rachieru P, Brion A, Berthou C, Bay JO, Delepine R, Desablens B, Camilleri-Broët S, Linassier C, Lamy T. High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group. Bone Marrow Transplant. 2006 Sep;38(6):417-20. link to original article contains verified protocol PubMed
CYVE & G-CSF
back to top |
CYVE: CYtarabine, VEpesid (Etoposide)
Regimen
Study | Evidence |
Soussain et al. 2001 | Pilot, >20 pts |
Soussain et al. 2008 | Phase II |
Target collection dose not described; mobilization took place after the first course of CYVE salvage for CNS lymphoma.
Chemotherapy
- Cytarabine (Cytosar) as follows:
- 2000 mg/m2 IV over 3 hours once per day on days 2 to 5
- 50 mg/m2 IV over 12 hours once per day on days 1 to 5
- Etoposide (Vepesid) 200 mg/m2 IV over 2 hours once per day on days 2 to 5
Growth factor therapy
- Filgrastim (Neupogen) 5 mcg/kg SC once per day starting 48 hours after end of chemotherapy
References
- Soussain C, Suzan F, Hoang-Xuan K, Cassoux N, Levy V, Azar N, Belanger C, Achour E, Ribrag V, Gerber S, Delattre JY, Leblond V. Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. J Clin Oncol. 2001 Feb 1;19(3):742-9. link to original article contains verified protocol PubMed
- Soussain C, Hoang-Xuan K, Taillandier L, Fourme E, Choquet S, Witz F, Casasnovas O, Dupriez B, Souleau B, Taksin AL, Gisselbrecht C, Jaccard A, Omuro A, Sanson M, Janvier M, Kolb B, Zini JM, Leblond V; Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire. Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire. J Clin Oncol. 2008 May 20;26(15):2512-8. Epub 2008 Apr 14. link to original article contains verified protocol PubMed
IGEV & Lenograstim
back to top |
IGEV: Ifosfamide, GEmcitabine, Vinorelbine
Regimen
Study | Evidence |
Magagnoli et al. 2007 | Phase II |
Chemotherapy
- Ifosfamide (Ifex) 2000 mg/m2 IV over 2 hours once per day on days 1 to 4
- Gemcitabine (Gemzar) 800 mg/m2 IV once per day on days 1 & 4
- Vinorelbine (Navelbine) 20 mg/m2 IV once on day 1
- Prednisolone (Millipred) 100 mg PO once per day on days 1 to 4
Supportive medications
- Mesna (Mesnex) 900 mg/m2 IV at 0, 2, 4 hours after Ifosfamide (Ifex) on days 1 to 4
- Lenograstim (Granocyte) 263 mcg SC once per day on days 7 until at least 3 x 106 CD34+ cells per kg of body weight were collected
Apheresis was performed when the peripheral blood CD34+ cell count exceeded 10 cells/ul.
References
- Magagnoli M, Spina M, Balzarotti M, Timofeeva I, Isa L, Michieli M, Capizzuto R, Morenghi E, Castagna L, Tirelli U, Santoro A. IGEV regimen and a fixed dose of lenograstim: an effective mobilization regimen in pretreated Hodgkin's lymphoma patients. Bone Marrow Transplant. 2007 Dec;40(11):1019-25. Epub 2007 Oct 1. link to original article contains verified protocol PubMed
DexaBEAM & G-CSF
back to top |
DexaBEAM: Rituximab, Dexamethasone, BiCNU (Carmustine), Etoposide, Ara-C (Cytarabine), Melphalan
Regimen
Study | Evidence |
Dreyling et al. 2004 | Non-randomized portion of RCT |
Chemotherapy
- Dexamethasone (Decadron) 8 mg PO TID on days 1 to 10
- Carmustine (BiCNU) 60 mg/m2 IV once on day 2
- Etoposide (Vepesid) 75 mg/m2 IV once per day on days 4 to 7
- Cytarabine (Cytosar) 100 mg/m2 IV BID on days 4 to 7
- Melphalan (Alkeran) 20 mg/m2 IV once on day 3
Growth factor therapy
- G-CSF starting on day 11
A minimum of 1 × 106 CD34+ cells/kg are collected.
References
- Dreyling M, Lenz G, Hoster E, Van Hoof A, Gisselbrecht C, Schmits R, Metzner B, Truemper L, Reiser M, Steinhauer H, Boiron JM, Boogaerts MA, Aldaoud A, Silingardi V, Kluin-Nelemans HC, Hasford J, Parwaresch R, Unterhalt M, Hiddemann W. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood. 2005 Apr 1;105(7):2677-84. Epub 2004 Dec 9. link to original article contains verified protocol PubMed